View
216
Download
2
Category
Preview:
Citation preview
Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.D.
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Why invite a value discussion?
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Clinically Meaningful Outcomes and Implications for Value (Ellis, et al.,J Clin Oncol. 2014 Apr 20;32(12):1277-80
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Moving the Discussion to Value it’s far more than Cost
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Seeking an Association Between Clinical Benefit, Toxicity and Cost
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Phase III ALTTO trial <br />The ALTTO trial did not meet its endpoints (DFS): Neither the L + T vs. T comparison nor the T → L vs. T comparison<br />
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
<br /> Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Presented By Lowell Schnipper at 2014 ASCO Annual Meeting
Recommended